AXIS Healthcare Consulting Ltd

🎄 As 2024 comes to a close, we reflect on an incredible year at AXIS. 🎄 We kicked off the year with a new chapter and the exciting journey of growth and expansion as reimbursement specialists across the UK and Ireland. What a year it has been! At AXIS, our people are our greatest asset and this year, we were thrilled to welcome several new talented individuals to our team: Anne-Marie Barnes in January, Allister Upton in March, Karen Stanford PhD, Samuel E. Taylor (PhD), and Emma McGrath all joined in the summer and most recently, Loretta Trayors and Ann-Marie Scanlon joined in November, expanding us to a team of 16! Together, we continue to provide tailored solutions to our clients, ensuring that every submission is handled with care, integrity, and precision. Our expertise lies in our ability to collaborate, strategise, and drive efficient reimbursement pathways across the UK and Ireland, always with a focus on improving patient access to vital treatments. We’re proud of what we’ve achieved in 2024 and look forward to even more growth in 2025, including the exciting announcement of additional team members (👀 this space!!) Last week we all met together in person for our Christmas Dinner at the gibson hotel to celebrate our success and to raise a glass to a bright future for #TeamAXIS and the continued success of our clients! We acknowledge the support of Enterprise Ireland, Enterprise Ireland UK, Platform94, Greater Manchester Chamber, UK, Prosperity Chambers, Causeway: Ireland Scotland Business Exchange and a very special thank you to our founder and CEO Brenda Dooley for your belief in the team and your vision for AXIS to be THE Reimbursement Experts in Ireland and the UK. Wishing everyone a joyful holiday season and a Happy New Year! 🎉 #reimbursementexperts #bestteamever #marketaccess #HTA #UK #Ireland #growth #patientaccess #thatsawrapfor2024

Have you seen NICE are planning to update the HST eligibility criteria, with the opportunity to comment until 5pm 30th Jan? Our NICE expert Carl Prescott gives his thoughts below: “The current criteria are more subjective than these suggested updates. Too much subjectivity can mean a lack of clarity, confusion, and potentially a perception of unfairness if there are disagreements about whether a new medicine is eligible for HST or not. The new criteria have extra detail outlining more objectively what is expected in order to be eligible. Therefore even if you disagree with the criteria, at least everyone should be clearer on where they stand”. https://lnkd.in/eMRnbG6y Get in touch with Carl Prescott if you want to discuss this in more detail, or to hear about his experiences of working with the HST criteria when he was at NICE. 

Carl Prescott, our Senior Director for Pipeline and Early Access Strategy, attended NICE’s webinar earlier on “Navigating the future: AI at NICE”. Here are his key takeaways: 💊NICE has 2 important documents on its website for AI in HTA. These are: the Position Statement, and the Statement of Intent. Although similarly named, the Position Statement is about current best practice, and the Statement of Intent is about the future: -POSITION STATEMENT: Sets out the standards/good practice NICE expects from submitting companies if they have used AI methods in their submissions (which in turn supports NICE committee members and EAGs in being clear on the standards to expect) (https://lnkd.in/gu5-9_Kn) -STATEMENT OF INTENT: Sets out what NICE will be doing to develop and test methods to support the use and evaluation of AI at NICE in future. This is in 3 key areas: Guidance (i.e. supporting technology developers when they want to use AI as part of their methods to generate evidence), evaluation (i.e. how to evaluate technologies which actually use AI) and Use (i.e. AI to improve NICE’s own internal processes). (https://lnkd.in/g8rB2Akg) 💊The Statement of Intent makes clear that developing the evidence requirements and piloting new tools in these priority areas will require close collaboration with key experts and stakeholders, including healthcare professionals, patients, researchers and life sciences industry representatives. 💊Examples of previous AI use at NICE were outlined. For example: -Internally at NICE, to assist with manual screening in clinical guidelines -A submitting company used AI techniques to adjust data to reduce confounding. 💊It was emphasised that the use of AI is around supporting the individual rather than replacing them, making things quicker but maintaining robustness. For submitting organisations, they remain accountable for the content of the submission. AI use should balance risks and benefits and only be used where there is value. 💊For more information, see NICE’s Position Statement and Statement of Intent in full (hyperlinked above). In addition, the AI and digital regulations service was also noted as a useful resource. This is a collaboration between NICE, MHRA, HRA and CQC to map out the regulatory and HTA pathway (https://lnkd.in/gpYp8-vb). If you’d like to discuss any of this further, get in touch with our NICE expert Carl Prescott who will be able to give a steer based on his 13 years at NICE, which included working on NICE Methods for HTA

One week on from our Women Leaders Networking Dinner in Barcelona alongside the ISPOR—The Professional Society for Health Economics and Outcomes Research European meet where we welcomed female leaders from the HEOR and Market Access community to come together for an evening of powerful networking and exchange. It was a truly fantastic evening filled with thought-provoking discussions, inspiring ideas and the formation of meaningful new connections. We would like to offer a special thank you to our incredible speakers; Anne Willemsen Funmi Oluwa and Silvy Mardiguian, whose insights and perspectives set the tone for such a dynamic and engaging evening. Esther Nzenza and I are so proud to have co created this platform which fosters meaningful connections amongst women leaders and affords a confidential & collaborative space for us to learn from each other while authentically embracing our leadership abilities and natural strengths. The chance to share stories, journeys and reflections is very special and we are delighted that we're able to facilitate such an opportunity. We also had the chance to start a dialogue around where this community might evolve to next - with an active linked in group ensuring we can all remain connected and providing a platform for all members to share content and ideas that are relevant to our space. If you’re a female leader in HEOR or Market Access working within a pharmaceutical or biotech company and would like to be a part of our community join here: https://lnkd.in/evygNRcW to connect, share insights and help spread the word about exciting opportunities. Together, we can learn, grow, and create new possibilities. We plan to convene another event alongside the EPA in Amsterdam next spring and would love to see you there. AXIS Healthcare Consulting Ltd EMIG - Ethical Medicines Industry Group The Association of the British Pharmaceutical Industry (ABPI)IPHA #marketaccess #HEOR #HTA #womenleaders #womensupportingwomen

This day last week AXIS was at Day 1 of ISPOR Europe 2024 ... we cannot believe a week has already gone by, we just had to share some of our highlights 😊 #ISPOREurope #conference #exhibitor #marketaccess #HEOR #reimbursement #hta #reimbursementexperts #TeamAXIS Enterprise Ireland Enterprise Ireland UK ISPOR—The Professional Society for Health Economics and Outcomes Research Brenda Dooley Allister Upton Carl Prescott Caroline McNeill Emma McGrath

It is the final day of #ISPOREurope 2024 and what a conference it has been. Lots of great learnings and insights which we will be sharing over the coming days. We presented 7 research posters, two of which were in the Top 5% and we must credit our incredible team for all the hard work that went into developing the research, massive thank you and well done to Emer Gribbon, David McLoughlin, Jennifer L., Katherine M., Mohamed Zein, Manpreet Kaur, Anne-Marie Barnes, Emma McGrath, Carl Prescott and Brenda Dooley 😁 Brenda was super busy presenting this year and below she gives an overview of one of our Top5% posters 'Time to Reimbursement in Ireland; Utilising Regression Analysis to Assess Factors Contributing to Overall Timelines'. As always the highlight has been getting to meet current and potential clients and friends in person. A huge thank you to our team on the ground in Barcelona and to the rest of the team who were keeping the show on the road while we were away, thank you to all our clients and trusted associates who visited our stand and to all those who dropped by to say hello. And finally thank you ISPOR—The Professional Society for Health Economics and Outcomes Research for a really great conference. We will see you all again next year - a little closer to home in Glasgow 😊 #itsateameffort #ISPOR #exhibition #HEOR #reimbursement #marketaccess #reimbursementexperts #TeamAXIS

Another very successful day for #TeamAXIS at #ISPOREurope at Stand 1127. Brenda Dooley, Allister Upton, Carl Prescott, Caroline McNeill and Emma McGrath have been enjoying meeting and speaking with the other attendees. #ISPOR #exhibition #networking #reimbursementexperts

Emma McGrath attended the short course Technology Assessment for Rare Diseases on Sunday as part of #ISPOREurope 2024. She captures her learnings below. Speakers: Hwee-Lin Wee -Lin Wee, PhD joshua byrnes , PhD Diana Beatriz Bayani, MSc, PhD Session 1: Overview of rare diseases Looking at the case study of Spinal Muscular Atrophy (SMA) Limited research and development to receiving treatments for rare diseases such as regulatory barriers, recruitment and unpredictability. The European Organisation for Rare Diseases (EURORDIS) and the Orphan Drug regulation initiatives to encourage R&D for rare diseases. Singapore’s approach to finance rare diseases addressing the need for an appropriate financing framework, that is both sustainable and will prevent a schism between those who can afford precision medicine and those who cannot. Session 2: Comparing the Experiences of England and Singapore. Key features of rare disease policies, HTA pathways and funding Case Studies: Comparing the experiences of England and Singapore Implications for future policy and practice Session 3: Economic Evaluation of rare diseases Types of economic evaluation Cost-effectiveness planes and quantifying the uncertainty Spotlight on extrapolations and their uncertainty over time Session 4: Multicriteria Analysis (MCDA) requires the aggregation of criteria into a single expression of value. MCDA has been used to organise data and questions relevant to the development of clinical practice guidelines (CPG) for a rare genetic condition, Prader-Willi syndrome (PWS) Pros of MCDA are how it Improves transparency, promotes consistency, Does not replace judgement Cons of MCDA: Requires careful design considerations and is time consuming. #shortcourse #ISPOR #learning #raredisease #economicevaluation #multicriteriaanalysis

If you are attending #ISPOREurope be sure and drop by the AXIS stand, Stand 1127 to connect in person with our team, Brenda Dooley , Allister Upton, Carl Prescott, Caroline McNeill and Emma McGrath will be delighted to meet you. AXIS have 7 research posters across the three days and the senior team still have some availability to meet for 1:1 sessions just check out https://lnkd.in/gGtNku94 to see the posters in full and for your link to book with the team. #exhibition #ISPOR #marketaccess #reimbursementexperts #hta #ukandireland #TeamAXIS

AXIS are all set for #ISPOREurope 24. One of our highlights will definitely be our Women Leaders event jointly hosted by AXIS and Decisive Consulting Ltd which takes place tomorrow evening. Below Brenda introduces Silvy Mardiguian who will speak at the event. We are genuinely so happy and excited to have Silvy and our other speakers Funmi Oluwa and Anne Willemsen speak to us about their individual journeys #womensupportingwomen #networkdinner #femaleleaders